Abstract
The clearance of colloidal particles from the blood circulation occurs by phagocytes and/or endothelial cells, mainly in the liver, the spleen, and the bone marrow. The relative distribution of the injected particles in these organs is known to depend on various factors such as the size and surface properties of the particles and the type of serum proteins adsorbed onto the surface of particles. The basic principles behind their distribution characteristics into the reticuloendothelial system, however, remain unclear. This article reviews major determinants in hepatic disposition of polystyrene nanospheres, especially the relationship among physicochemical properties of the particle surface, the type of blood components associated onto the surface of particles, and their in vivo disposition characteristics in rats, and considerations to be given and implication for the rational design of particulate drug carriers are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 277-306 |
| Number of pages | 30 |
| Journal | Critical Reviews in Therapeutic Drug Carrier Systems |
| Volume | 19 |
| Issue number | 4-5 |
| DOIs | |
| Publication status | Published - 2002 |
Fingerprint
Keywords
- Dysopsonin
- Opsonin
- Perfused rat liver
- Polystyrene nanosphere
- Receptor-mediated phagocytosis
ASJC Scopus subject areas
- Pharmacology
Cite this
Major determinants in hepatic disposition of polystyrene nanospheres : Implication for rational design of particulate drug carriers. / Ogawara, Ken ichi; Higaki, Kazutaka; Kimura, Toshikiro.
In: Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 19, No. 4-5, 2002, p. 277-306.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Major determinants in hepatic disposition of polystyrene nanospheres
T2 - Implication for rational design of particulate drug carriers
AU - Ogawara, Ken ichi
AU - Higaki, Kazutaka
AU - Kimura, Toshikiro
PY - 2002
Y1 - 2002
N2 - The clearance of colloidal particles from the blood circulation occurs by phagocytes and/or endothelial cells, mainly in the liver, the spleen, and the bone marrow. The relative distribution of the injected particles in these organs is known to depend on various factors such as the size and surface properties of the particles and the type of serum proteins adsorbed onto the surface of particles. The basic principles behind their distribution characteristics into the reticuloendothelial system, however, remain unclear. This article reviews major determinants in hepatic disposition of polystyrene nanospheres, especially the relationship among physicochemical properties of the particle surface, the type of blood components associated onto the surface of particles, and their in vivo disposition characteristics in rats, and considerations to be given and implication for the rational design of particulate drug carriers are discussed.
AB - The clearance of colloidal particles from the blood circulation occurs by phagocytes and/or endothelial cells, mainly in the liver, the spleen, and the bone marrow. The relative distribution of the injected particles in these organs is known to depend on various factors such as the size and surface properties of the particles and the type of serum proteins adsorbed onto the surface of particles. The basic principles behind their distribution characteristics into the reticuloendothelial system, however, remain unclear. This article reviews major determinants in hepatic disposition of polystyrene nanospheres, especially the relationship among physicochemical properties of the particle surface, the type of blood components associated onto the surface of particles, and their in vivo disposition characteristics in rats, and considerations to be given and implication for the rational design of particulate drug carriers are discussed.
KW - Dysopsonin
KW - Opsonin
KW - Perfused rat liver
KW - Polystyrene nanosphere
KW - Receptor-mediated phagocytosis
UR - http://www.scopus.com/inward/record.url?scp=0036936242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036936242&partnerID=8YFLogxK
U2 - 10.1615/CritRevTherDrugCarrierSyst.v19.i45.10
DO - 10.1615/CritRevTherDrugCarrierSyst.v19.i45.10
M3 - Article
VL - 19
SP - 277
EP - 306
JO - Critical Reviews in Therapeutic Drug Carrier Systems
JF - Critical Reviews in Therapeutic Drug Carrier Systems
SN - 0743-4863
IS - 4-5
ER -